Group 1 - The core viewpoint of the article highlights the target price increases for listed companies, with notable gains for Stone Technology and LiuGong, showing increases of 47.62% and 38.08% respectively, indicating strong market confidence in these companies [1][2] - On December 30, a total of 29 listed companies received broker recommendations, with GuiGuan Electric and LiuGong each receiving two recommendations, reflecting their strong market positions in the electric power and engineering machinery sectors [3] Group 2 - On the downgrade side, only one company, Sanxia Tourism, had its rating lowered by CITIC Securities from "Buy" to "Hold," indicating a cautious outlook for this company in the tourism and scenic area [4][5] - A total of 11 companies received initial coverage from brokers on December 30, with notable mentions including Wanwei High-tech receiving a "Recommended" rating from China Galaxy Securities and LiuGong receiving a "Strong Buy" rating from Huachuang Securities, showcasing the interest in these sectors [6]

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司（以下简称"公司"）全资子公 司江西滕王阁药业有限公司（以下简称"滕王阁药业"）于近日 收到由江西省科学技术厅、江西省财政厅、国家税务总局江西省 税务局联合颁发的《高新技术企业证书》被认定为高新技术企业。 证书编号为GR202536000426，有效期三年。 根据国家相关规定，本次通过高新技术企业认定后，滕王阁 药业将连续三年享受国家关于高新技术企业的所得税优惠政策， 即按15%的税率缴纳企业所得税，本次滕王阁药业通过高新技术 企业认定事项不会对公司当期经营业绩产生重大影响。 滕王阁药业此次被认定为高新技术企业，有利于进一步提升 创新能力、增强市场竞争力。 特此公告 湖南方盛制药股份有限公司董事会 2025年12月30日 证券代码：603998 证券简称：方盛制药 公告编号：2025-106 湖南方盛制药股份有限公司 关于全资子公司再次被认定为高新技术企业的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担 ...

格隆汇12月30日丨方盛制药(603998.SH)公布，公司全资子公司江西滕王阁药业有限公司（以下简称"滕 王阁药业"）于近日收到由江西省科学技术厅、江西省财政厅、国家税务总局江西省税务局联合颁发的 《高新技术企业证书》被认定为高新技术企业。证书编号为GR202536000426，有效期三年。滕王阁药 业此次被认定为高新技术企业，有利于进一步提升创新能力、增强市场竞争力。 ...

Core Viewpoint - The inclusion of Fangsheng Pharmaceutical's innovative traditional Chinese medicine, Yangxue Qufeng Zhitong Granules, in the "2025 Medical Insurance Catalog" is expected to enhance the company's growth momentum and positively impact its market promotion, hospital access, and sales scale [1] Group 1: Product Development and Market Impact - Yangxue Qufeng Zhitong Granules, developed independently by the company, has been included in the "2025 Medical Insurance Catalog" after negotiations, which is anticipated to boost the company's future operating performance and market share [1] - In addition to Yangxue Qufeng Zhitong Granules, other innovative traditional Chinese medicines developed by the company, such as Xiaoyi Jingxing Zhikou Granules and Xuanqi Jiangu Pian, are also included in the "2025 Medical Insurance Catalog" [1] - The company has received clinical approval for Xiangqin Jiere Granules and Ziying Granules in July and August 2025, further expanding its product portfolio [1] Group 2: Strategic Direction - The company has established a development strategy to become a health industry group centered on innovative traditional Chinese medicine [1] - There will be a continuous increase in research and development investment and market cultivation efforts for innovative traditional Chinese medicine to enhance core competitive advantages [1] - The initial coverage of the company has been rated as "Buy" [1]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The inclusion of the innovative traditional Chinese medicine product, Yangxue Qufeng Zhitong Granules, in the 2025 National Medical Insurance Directory is expected to enhance market promotion, hospital access, and sales scale, positively impacting the company's future operating performance and market share [4]. - The product has demonstrated good efficacy and safety in clinical trials, showing advantages over Western medicine in treating recurrent tension-type headaches [5]. - The company has additional innovative traditional Chinese medicine products included in the insurance directory, indicating a strong pipeline for future growth [6]. - Revenue forecasts for 2025-2027 are projected at 1.828 billion, 2.023 billion, and 2.247 billion yuan, with net profits of 301 million, 364 million, and 439 million yuan respectively, suggesting a favorable valuation with current PE ratios of 16, 13, and 11 times [7]. Company Overview - The latest closing price of the company's stock is 11.11 yuan, with a total market capitalization of 4.9 billion yuan [3]. - The company has a total share capital of 439 million shares, with an asset-liability ratio of 46.9% and a current PE ratio of 18.83 [3].

Core Viewpoint - Fangsheng Pharmaceutical (603998) is focusing on the development of innovative traditional Chinese medicine (TCM) products, with plans to enhance its product pipeline and achieve significant sales growth in the coming years [1] Company Announcements - The company held a product launch event for its new product, Yao Xue Qu Feng Zhi Tong Granules, on December 21, 2025, discussing its operational status, R&D progress, and market strategy [1] - Yao Xue Qu Feng Zhi Tong Granules has been included in the 2025 National Medical Insurance Directory, with plans to cover over 500 medical institutions by 2026 [2] - Fangsheng Pharmaceutical has successfully launched two innovative TCM products and aims to create a product matrix with annual sales of 300-500 million yuan [2] - The industrial hemp subsidiary has achieved large-scale production and overseas sales [2]

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Core Viewpoint - The Chinese pharmaceutical industry is increasingly focusing on innovation, with leading companies like Fangsheng Pharmaceutical adopting a research-driven development approach, supported by favorable policies for traditional Chinese medicine (TCM) innovation drugs [2][3]. Group 1: Product Launch and Market Strategy - Fangsheng Pharmaceutical launched its new product, "Yangxue Qufeng Zhitong Granules," which is the first TCM innovation drug for frequent tension-type headaches, and it has been included in the national medical insurance directory [3][4]. - The company aims to cover over 500 public medical institutions by 2026 and achieve sales revenue exceeding that of its previous TCM innovation drug, "Xuanqi Jianguo Pian" [3][4]. Group 2: R&D Focus and Pipeline - Fangsheng Pharmaceutical is concentrating on innovative TCM research while also developing modified TCM drugs and chemical generics, with plans to explore chemical and biological innovation drugs [4][5]. - The company has a growing product pipeline, including several TCM innovation drugs that have received clinical trial approvals, such as "Yiqi Xiaoliu Granules" and "Ziying Granules" [4][5]. Group 3: Financial Performance and Shareholder Returns - Since its listing, Fangsheng Pharmaceutical has distributed dividends 17 times, totaling approximately 689 million yuan (including tax), and has implemented multiple dividend distributions annually since 2020 [6]. - The company is focusing on enhancing its operational capabilities and product market access to support its growth strategy [6][7]. Group 4: Industrial Hemp Development - Fangsheng Pharmaceutical's subsidiary, Yunnan Fuya Biotechnology Co., has achieved large-scale production of high-purity CBD and is expanding its global market presence [6][7]. - The company is adopting a combination of commissioned and independent research and development strategies to broaden the application scenarios of industrial hemp products [7].

Core Insights - The launch of "Yangxue Qufeng Zhitong Granules" marks a significant breakthrough for the company in the field of traditional Chinese medicine, filling a clinical gap for frequent tension-type headaches [1][2] - The product is expected to tap into a market worth over 100 billion yuan, with a patient population of 285 million in China suffering from tension-type headaches [2][3] Product Development and Market Strategy - The company has invested approximately 27 million yuan in the development of the new product, which received its drug registration certificate in June 2025 [2] - The granules have been included in the 2025 medical insurance directory, providing a solid foundation for market promotion and sales growth [2] - The company aims to cover over 500 public medical institutions and exceed the first-year sales revenue of its previous innovative product, Xuanqi Jiangu Pian, by 2026 [3] R&D and Innovation - The company has a strong focus on R&D, with 32 approved 1.1 category innovative traditional Chinese medicines in the past decade, of which three are from the company [3][4] - There are nearly 20 ongoing innovative traditional Chinese medicine projects, with three 1.1 category new drugs entering clinical stages [3] Future Growth Plans - The company plans to accelerate the development of its research pipeline over the next three years, aiming to transition from a follower to a leader in traditional Chinese medicine [4] - The goal is to create multiple products with annual sales of 300 million to 500 million yuan, ensuring steady growth in performance [4] - The company is also preparing for policy changes and new growth points by focusing on high-threshold generic drugs and enhancing its innovative drug output [4]